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Summary
Background Oestrogen use by postmenopausal women has
many health benefits, but findings on the effect of
oestrogen in Alzheimer’s disease are conflicting. Oestrogen
promotes the growth and survival of cholinergic neurons
and could decrease cerebral amyloid deposition, both of
which may delay the onset or prevent Alzheimer’s disease.
To investigate whether use of oestrogen during the
postmenopausal period affects the risk of Alzheimer’s
disease, we studied 1124 elderly women who were initially
free of Alzheimer’s disease, Parkinson’s disease, and
stroke, and who were taking part in a longitudinal study of
ageing and health in a New York City community.
Methods Relative risks and age-at-onset distributions were
calculated from simple and adjusted Cox proportional
hazards models. Standard annual clinical assessments and
criterion-based diagnoses were used in follow-up (range 1–5
years).
Findings Overall, 156 (12·5%) women reported taking
oestrogen after onset of menopause. The age at onset of
Alzheimer’s disease was significantly later in women who
had taken oestrogen than in those who did not and the
relative risk of the disease was significantly reduced
(9/156 [5·8%] oestrogen users vs 158/968 [16·3%] non-
users; 0·40 [95% CI 0·22–0·85], p<0·01), even after
adjustment for differences in education, ethnic origin, and
apolipoprotein-E genotype. Women who had used oestrogen
for longer than 1 year had a greater reduction in risk; none
of 23 women who were taking oestrogen at study enrolment
has developed Alzheimer’s disease.
Interpretation Oestrogen use in postmenopausal women
may delay the onset and decrease the risk of Alzheimer’s
disease. Prospective studies are needed to establish the
dose and duration of oestrogen required to provide this
benefit and to assess its safety in elderly postmenopausal
women.
Lancet 1996; 348: 429–32
See Commentary page 420
Introduction
Use of oestrogen by postmenopausal women has many
health benefits.1,2 Oestrogen has been used as a treatment3,4
for Alzheimer’s disease, which affects a substantial
proportion of elderly women.5 One study reported that
oestrogen use was associated with a lower risk of mortality
related to Alzheimer’s disease,6 although a subsequent
case-control study did not confirm this association.7
Oestrogen promotes the growth of cholinergic neurons,8,9
stimulates the secretase metabolism of the amyloid
precursor protein,10 and may interact with apolipoprotein
E.11 All these factors could affect the risk of Alzheimer’s
disease.
We examined the effect of a history of oestrogen use on
the development of Alzheimer’s disease among elderly
women living in New York. Our hypothesis was that
oestrogen use might lower the risk of incident Alzheimer’s
disease.
Methods
1282 non-demented elderly women were identified in a
community-based study of ageing in northern Manhattan, New
York City. The Health Care Financing Administration provided
access to a random sample of Medicare recipients in the
community. Additional potential participants were consecutively
identified from records at senior centres and elderly housing sites
in the same community. We wrote to potential participants
identified by either method explaining that they had been selected
to take part in a study of ageing. Participation rates were 77% at
the senior centres and housing sites and 72% in the Medicare
sample; these rates did not differ by ethnic origin. Each
participant underwent a 90 min face-to-face interview then a
standard assessment, which included a medical history, physical
and neurological examination, and a brief (about 1 h) battery of
neuropsychological tests.12,13 The criteria for eligibility were: no
evidence of cognitive impairment on detailed psychometric
assessment at the initial interview; no history of stroke or
Parkinson’s disease; and at least one subsequent annual follow-up
assessment.
Information about oestrogen use was available for 1227
(95·7%) women. From this group we excluded 52 (4·2%) women
with Parkinson’s disease, 45 (3·7%) with stroke, and six (0·5%)
with both disorders. Thus, we restricted the analysis to 1124
women—352 (31%) women identified at the senior centres and
housing sites and 772 (69%) from the Medicare sample. The
Columbia University Institutional Review Board reviewed and
approved this project.
A standard history of oral oestrogen use was obtained from all
women at study entry by a trained interviewer as part of the risk-
factor questionnaire. The test-retest reliability of the overall
questionnaire had been previously established.14 Questions about
oestrogen use had good test-retest reliability (κ=0·65). If a
woman had ever taken oestrogen, she was asked the ages at which
she began and stopped. She was asked how old she was at the
onset of the menopause and whether it occurred naturally or as a
result of surgery. We asked the women to name the type of
oestrogen preparation they used but not the dosages.
For diagnosis of dementia, medical records and imaging
studies were used, as well as data from the initial and follow-up
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p=0·001). Age at menopause was similar for women who
did and did not develop Alzheimer’s disease.
156 women reported that they had used oestrogen after
the onset of the menopause. The average duration of
oestrogen use was 6·8 years (range 2 months to 49 years).
Women who had used oestrogen were younger than those
who had not (73·0 [6·3] vs 74·4 [7·1] years, p=0·01) and
had had more years of education (10·2 [4·8] vs 9·0 [4·5]
years, p=0·005). Fewer African-American women than
caucasian or Hispanic women had used oestrogen (41
[10·3%] vs 115 [15·9%], p=0·007). Women who took
oestrogen were more likely than those who did not to have
had a hysterectomy (78 [50·0%] vs 256 [26·4%],
p=0·0001), and to have had onset of the menopause at an
earlier age (45·4 [8·1] vs 47·0 [7·7], p=0·06). A greater
proportion of women who had undergone hysterectomy
than of those who had natural menopauses had used
oestrogen for longer than 1 year (23/227 [10·1%] vs
35/897 [4·0%], p=0·0001). The majority of women used
tablets containing conjugated oestrogens (Premarin). The
most frequent reasons for discontinuation of oestrogen use
were uterine bleeding, fear of cancer, or physician’s
advice.
A history of oestrogen use was significantly less
common among women who developed Alzheimer’s
disease than in women who remained free of the disease
(table 1, p=0·0006). There was no difference in the use of
oestrogen between the women excluded at baseline for
Parkinson’s disease or stroke and the disease-free women
(Parkinson’s disease 17%, stroke 10%, disease-free 16%,
p=0·51).
The age at onset for Alzheimer’s disease, stratified by
the median age at entry into the study, was significantly
later among women who used oestrogen than among
women who never used oestrogen (log-rank test p<0·01).
The relative risk of Alzheimer’s disease associated with a
history of oestrogen use was 0·40 (95% CI 0·22–0·85;
p=0·01, table 1). Adjustment for ethnic group, years of
education, and participation group (senior centre or
housing vs Medicare sample) did not significantly change
the relative risk (0·5 [0·25–0·9], p=0·02).
The Cox proportional hazards model was also used to
examine the effect of duration of oestrogen use on the risk
of Alzheimer’s disease (table 2). 31 (20%) oestrogen users
did not recall their duration of oestrogen use. The
association with Alzheimer’s disease among these women
(unknown group in table 2) was not significantly different
from that in non-users, which suggests that they may not
have used oestrogen at all or for only a brief period.
Women who took oestrogen for 1 year or less (average 4
months) had a lower risk of Alzheimer’s disease than
never-users, of borderline statistical significance (p=0·06).
The relative risk of Alzheimer’s disease for women who
took oestrogen for longer than a year (average 13·6 years)
was significantly reduced (0·13 [0·02–0·92], p<0·01).
There was a significant linear trend in the effect of
duration of oestrogen use on disease risk (log-rank test,
p=0·0034, figure). 23 women were still taking oestrogen at
enrolment in the study, and none has developed
Alzheimer’s disease during the study period.
To check the assumptions of the Cox regression model,
we plotted the martingale residuals against age at onset.19
Data for all but three subjects fell within the predicted
horizontal band around 0, satisfying the assumptions of
proportional hazards.
Among women whose data satisfied criteria for
study examinations. The diagnosis was established by consensus
among an independent group of physicians and neuro-
psychologists from this information. This group were not aware of
information on oestrogen use at any point during the diagnostic
process. The diagnosis of dementia15 required evidence of
cognitive decline on the neuropsychological test battery and
impairment in social or occupational function. All data were
examined to identify the aetiology of dementia with standard
criteria16 for the diagnosis of Alzheimer’s disease.
Ethnic origin was classified by self-report on the format of the
1990 United States Census Bureau (Census of Population and
Housing, 1990).
For apolipoprotein E (APOE) genotyping, genomic DNA was
amplified by PCR, and subjected to CfoI restriction analysis with
APOE primers and conditions modified from those described by
Hixson and Vernier.17,18
Demographic characteristics and a history of oestrogen use in
women who did and did not develop Alzheimer’s disease were
compared by means of χ2 tests for categorical variables and
ANOVA for continuous variables. Age, ethnic origin, and
education were compared among women who did and women
who did not use oestrogen, and then among those who did and
did not develop Alzheimer’s disease.
The Cox proportional hazard model was used to calculate the
relative risk of developing Alzheimer’s disease associated with use
of oestrogen, and survival analysis was used to plot the age-at-
onset distributions for women who did and did not use oestrogen.
Subsequent models were stratified to assess the effects of
education, APOE genotype, and ethnic origin on the relative risk;
these covariates were then included in multivariate models.
Because older women entering the study had a higher probability
of developing Alzheimer’s disease than younger women, we
stratified the analysis by the median age at baseline to reduce a
possible age cohort effect. We used martingale methods to check
the proportional hazards assumption.19 The annual incidence rate
was estimated and the incidence rate ratio was calculated by
standard methods.
Results
The mean age of the participating women was 74·2 years
(SD 7·0) and the mean duration of education 9·2 years
(SD 4·6). 400 (36%) of the women were African-
American, 431 (38%) were Hispanic, and 293 (26%) were
caucasian. During follow-up, which ranged from 1 to 5
years after the initial interview, 167 (14·9%) women
developed Alzheimer’s disease. The women who
developed Alzheimer’s disease were older than those who
did not (78·5 [7·7] vs 73·7 [6·6] years, p=0·001) and had
had fewer years of education (6·7 [4·2] vs 9·6 [4·5] years,
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At risk Alzheimer’s Healthy Relative risk
disease* (95% CI)
No oestrogen use 968 158 (16·3%) 810 1·0
Oestrogen use 156 9 (5·8%) 147 0·40 (0·22–0·85)
Total 1124 167 (14·9%) 957
*Total number of incident cases over whole study period (cumulative incidence).
Table 1: Relative risk of incident Alzheimer’s disease
associated with use of oestrogen during postmenopausal
period
Oestrogen use At risk Alzheimer’s Healthy Relative risk
disease* (95% CI)
None 968 158 (16·3%) 810 1·0
Unknown 31 3 (9·7%) 28 1·3 (0·40–4·20)
1 year 67 5 (7·5%) 62 0·47 (0·20–1·10)
>1 year 58 1 (1·7%) 57 0·13 (0·02–0·92)
*Total number of incident cases over whole study period (cumulative incidence).
Table 2: Duration of oestrogen use
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inclusion in the analysis, 181 (16·1%) had no additional
follow-up information. These women were similar to the
943 with additional follow-up in age (mean 75·4 [SD 7·8]
vs 74·2 [6·8] years), education (9·3 [4·7] vs 9·2 [4·6]
years), ethnic origin (African-American 62 [34·3%] vs
other 338 [35·8%]), and oestrogen use (22 [12·5%] vs 134
[14·2%]). For women with additional follow-up, the
duration did not differ significantly by history of oestrogen
use or by the development of Alzheimer’s disease (p=0·7).
APOE genotypes were available for 604 (53·7%) of the
1124 women. The risk of incident Alzheimer’s disease
was higher for women with APOEε4 than for those with
other genotypes (ε4/ε4 3·9 [1·5–9·8]; one ε4 allele
1·2 [0·7–1·6]). None of the nine APOEε4 homozygous
women had taken oestrogen (three cases, six controls).
The relative risk for Alzheimer’s disease associated with
oestrogen use among APOEε4 heterozygous women was
reduced (0·13 [0·02–0·95]) as was that among women
with other APOE genotypes (0·4 [0·2–0·9]).
The estimated annual incidence rate of Alzheimer’s
disease was 2·7% among women who took oestrogen
compared with 8·4% among those who did not take
oestrogen. The overall incidence rate ratio was 0·4
(0·2–0·7), similar to that estimated in the Cox
proportional hazards model. 68 patients (41% of the 167
patients) showed mild impairment of cognitive function
but met criteria for inclusion. We repeated the analysis
after excluding these mildly impaired women to estimate
the relative risk of more advanced disease (n=99), but the
results of the Cox model were similar (relative risk
[0·25–0·9], p=0·04) as was the incidence rate ratio (0·24
[0·09–0·69]; incidence rate oestrogen 1·2% vs no
oestrogen 5·4%). The annual incidence rates are within
the ranges reported previously in East Boston.20
Discussion
These results suggest that a history of oestrogen use
during the postmenopausal period significantly delays the
onset of Alzheimer’s disease and lowers the risk of disease.
The duration of oestrogen use seems to be important in
risk reduction because women with a history of long-term
use had the lowest risk. Our study differs from previous
investigations of Alzheimer’s disease6,7 in that all women
were interviewed about the use of oestrogen and examined
before the onset of disease.
Paganini-Hill and Henderson6 reported a reduction with
oestrogen use in mortality related to Alzheimer’s disease in
a nested case-control study; 13 979 (61%) participants
completed a health survey by mail, but follow-up was
limited to health records and death certificates. Longer
periods of oestrogen use and younger age at menarche
were also associated with lower mortality.
Graves et al21 found no difference between patients with
Alzheimer’s disease and controls in the frequency of
oestrogen replacement, though sex distribution was not
described. Brenner and colleagues7 found no evidence that
oestrogen replacement therapy affected the risk of
Alzheimer’s disease; though no significant association was
observed, the odds ratio for oral oestrogen use associated
with Alzheimer’s disease was less than one. That study7
had sufficient power to detect a reduction in risk similar to
that in our study but the study design3 may explain why
the outcomes differ. Brenner and colleagues’ main
comparison was of the odds that patients with Alzheimer’s
disease used oestrogen and the odds that controls used
oestrogen. By contrast, we classified women on the basis
of a history of oestrogen use and compared the cumulative
risk that Alzheimer’s disease would develop among
oestrogen-users and never-users. Our results (figure) show
that oestrogen use does not prevent Alzheimer’s disease,
but that it seems to delay the onset of the disease. The
case-control design used by Brenner et al7 would not allow
examination of differences in the age-at-onset distribution.
Toran-Allerand and colleagues8 identified colocalisation
of oestrogen-receptor binding sites with the mRNA for
nerve growth factors and their receptors in developing
neurons of rodent basal forebrain.22 The degeneration of
these regions in Alzheimer’s disease may cause the loss of
memory and other cognitive functions. Their findings
imply that oestrogen and nerve growth factors influence
synthesis and release of nerve growth factors or
alternatively promote survival, differentiation,
regeneration, and plasticity. In a study of rats that had
undergone oophorectomy, those treated with 17β-
oestradiol did better on a memory task than those
deprived of oestrogen; these animals also showed
preservation of neurons in the basal forebrain as well as a
return to near-normal concentrations of mRNA for nerve
growth factors.9,23,24
Oestrogen protects hippocampal neurons in culture
exposed to excitotoxins, oxidative stress, or amyloid β.25
Cells cultured with 17β-oestradiol accumulate a soluble
form of the amyloid precursor protein by enhancing the
amount or activity of α-secretase.10 An exogenous source
of oestrogen in postmenopausal women, even for a limited
time, might foster the survival of neurons and limit the
amount of amyloid β deposition, thus delaying the onset of
overt manifestations of Alzheimer’s disease.
The association between APOEε4 and Alzheimer’s
disease has been extensively investigated,26,27 and our
results are similar to other population estimates.28
Oestrogen use was associated with a reduction in the risk
of Alzheimer’s disease among women heterozygous for ε4
and among women with other APOE genotypes, but we
were unable to assess the effect of oestrogen among
women homozygous for ε4.
This study has limitations because the design was
observational. Oestrogen use was assessed by history.
Oestrogen use was less common among African-American
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Figure: Survival analysis plot of distribution by age of
proportion of individuals remaining unaffected according to
duration of oestrogen use
Duration  of use >1 year, average=13·6 years; 1 year,
average=4 months. Women classified as unknown duration of use
(table 2) included in reference group.
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women and more likely among better-educated women.
Although we adjusted for some of these factors in our
analyses, we cannot exclude the possibility that oestrogen
use reflects a lifestyle characteristic or an as yet
unidentified exposure or bias that accounts for the effect
observed. We believe that a prospective trial of oestrogen
in perimenopausal women to delay the onset of
Alzheimer’s disease is justified, once more data on the
safety, dosage, and duration of oestrogen treatment
required become available.
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